Prophylactic hemofiltration in severely traumatized patients: effects on post-traumatic organ dysfunction syndrome

被引:24
作者
Bauer, M
Marzi, I
Ziegenfuss, T
Riegel, W
机构
[1] Univ Saarland, Klin Anaesthesiol & Intens Med, D-66421 Homburg, Germany
[2] Univ Saarland, Unfallchirurg Klin, D-66421 Homburg, Germany
[3] Univ Saarland, Klin Innere Med 4, D-66421 Homburg, Germany
关键词
multiple trauma; systemic inflammatory response syndrome; multiple organ dysfunction syndrome; continuous veno-venous hemofiltration; oxygen consumption; oxygen extraction; prospective randomized clinical trials;
D O I
10.1007/s001340000824
中图分类号
R4 [临床医学];
学科分类号
1002 [临床医学]; 100602 [中西医结合临床];
摘要
Objective: To evaluate the effects of prophylactic veno-venous hemofiltration (CVVH) in the absence of renal failure on multiple organ dysfunction syndrome after severe multiple trauma. Design: Prospective, randomized study. Setting: Intensive care unit (ICU) in a university hospital. Patients: Twenty-four patients with severe multiple trauma (injury severity score greater than or equal to 27), no renal failure on admission and no contraindication for moderate heparinization. Interventions: Twelve patients received conventional treatment while 12 patients were treated additionally with isovolemic CVVH for 5 days starting within 24 h following trauma. Signs of organ dysfunction were assessed daily including monitoring of systemic hemodynamics by means of pulmonary artery catheterization during the first 5 days after trauma. Measurements and main results: Prophylactic CVVH did not affect the overall severity of organ dysfunction as assessed by MOF or APACHE II scores. However, the pattern of impaired organ systems was influenced by CVVH: while the post-traumatic decrease in platelet count in patients subjected to CVVH was more pronounced than in controls (e.g. day 4: control: 115,080 +/- 15,087, CVVH: 57,383 +/- 4,201 mul(-1);p < 0.05) the development of hyperdynamic circulatory failure was simultaneously attenuated, as reflected by a limited increase in cardiac output and an attenuated decrease in systemic vascular resistance and oxygen extraction ratio (e.g systemic vascular resistance on day 4: control: 624.3 +/- 46.17, CVVH: 842.7 +/- 79.24 dyn(.)s(.)cm(-5); p < 0.005). Conclusion: CVVH blunts the cardiovascular response to multiple trauma and increases tissue oxygen extraction. However, the concomitant decrease in platelet counts represents a limitation for the use of prophylactic CVVH in surgical patients.
引用
收藏
页码:376 / 383
页数:8
相关论文
共 30 条
[1]
MULTIPLE ORGAN FAILURE SYNDROME IN THE 1990S - SYSTEMIC INFLAMMATORY RESPONSE AND ORGAN DYSFUNCTION [J].
BEAL, AL ;
CERRA, FB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (03) :226-233
[2]
AMERICAN-COLLEGE OF CHEST PHYSICIANS SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE - DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ ;
ABRAMS, JH ;
BERNARD, GR ;
BIONDI, JW ;
CALVIN, JE ;
DEMLING, R ;
FAHEY, PJ ;
FISHER, CJ ;
FRANKLIN, C ;
GORELICK, KJ ;
KELLEY, MA ;
MAKI, DG ;
MARSHALL, JC ;
MERRILL, WW ;
PRIBBLE, JP ;
RACKOW, EC ;
RODELL, TC ;
SHEAGREN, JN ;
SILVER, M ;
SPRUNG, CL ;
STRAUBE, RC ;
TOBIN, MJ ;
TRENHOLME, GM ;
WAGNER, DP ;
WEBB, CD ;
WHERRY, JC ;
WIEDEMANN, HP ;
WORTEL, CH .
CRITICAL CARE MEDICINE, 1992, 20 (06) :864-874
[3]
Sir Isaac Newton, sepsis, SIRS, and CARS [J].
Bone, RC .
CRITICAL CARE MEDICINE, 1996, 24 (07) :1125-1128
[4]
PLASMA CYTOKINE AND ENDOTOXIN LEVELS CORRELATE WITH SURVIVAL IN PATIENTS WITH THE SEPSIS SYNDROME [J].
CASEY, LC ;
BALK, RA ;
BONE, RC .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (08) :771-778
[5]
Can inflammatory cytokines be removed efficiently by continuous renal replacement therapies? [J].
De Vriese, AS ;
Vanholder, RC ;
Pascual, M ;
Lameire, NH ;
Colardyn, FA .
INTENSIVE CARE MEDICINE, 1999, 25 (09) :903-910
[6]
Post hoc analyses in sepsis trials: A formula for disappointment? [J].
Dellinger, RP .
CRITICAL CARE MEDICINE, 1996, 24 (05) :727-729
[7]
ECHTENACHER B, 1990, J IMMUNOL, V145, P3762
[8]
INITIAL EVALUATION OF HUMAN RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF SEPSIS SYNDROME - A RANDOMIZED, OPEN-LABEL, PLACEBO-CONTROLLED MULTICENTER TRIAL [J].
FISHER, CJ ;
SLOTMAN, GJ ;
OPAL, SM ;
PRIBBLE, JP ;
BONE, RC ;
EMMANUEL, G ;
NG, D ;
BLOEDOW, DC ;
CATALANO, MA ;
FRIEDMAN, B ;
MURE, A ;
SHAPIRO, E .
CRITICAL CARE MEDICINE, 1994, 22 (01) :12-21
[9]
FLEMING A, 1992, ARCH SURG-CHICAGO, V127, P1175
[10]
GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109